Mometasone furoate/formoterol in the treatment of persistent asthma

Expert Review of Respiratory Medicine

Volumn 5, Issue 6, 2011, Pages 739-746

  Berger, William E ^a  

^a Allergy & Asthma Associates of Northern California   (United States)

Author keywords

Anti inflammatory; Asthma; Asthma deterioration; Bronchodilator; Control; Corticosteroid; Exacerbation; Inhaler; Quality of life; agonist

Indexed keywords

FORMOTEROL FUMARATE; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; MOMETASONE FUROATE; PLACEBO;

ARTICLE; ASTHMA; CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; LUNG FUNCTION; QUALITY OF LIFE;

EID: 81255207996     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.71     Document Type: Article

References (32)

1. Pleis JR, Ward BW, Lucas JW. Summary health statistics for U. S. adults: National Health Interview Survey, 2009. National Center for Health Statistics. Vital Health Stat. 10(249), 1-217 (2010).
2. Bloom B, Cohen RA, Freeman G. Summary health statistics for US children: National Health Interview Survey, 2008. Vital Health Stat. 10(244), 1-81 (2009).
3. Barnett SB, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007. J. Allergy Clin. Immunol. 127, 145-152 (2011).
4. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N. Engl. J. Med. 362, 1169-1171 (2010).
5. Weinstein C, Staudinger H, Scott I et al. Dose counter performance of mometasone furoate/formoterol inhalers in subjects with asthma or COPD. Respir. Med. 105, 979-988 (2011).
6. Dulera®, prescribing information. Merck and Co. Inc. , Whitehouse Station, NJ, USA (2010).
7. Symbicort®, prescribing information. AstraZeneca, Wilmington, DE, USA (2009).
8. Advair Diskus®, prescribing information. GlaxoSmithKline, Research Triangle Park, NC, USA (2011).
9. Advair®, prescribing information. GlaxoSmithKline, Research Triangle Park, NC, USA (2011).
10. Meltzer EO, Kuna P, Nolte H et al. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur. Respr. J. doi:10. 1183/09031936. 00020310 (2011) (Epub ahead of print).
11. Popper TL, Gentles MJ, Kung TT et al. Structure-activity relationships of a series of novel topical corticosteroids. J. Steroid Biochem. 27, 837-843 (1987). (Pubitemid 18020143)
12. Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm. Pharmacol. Ther. 15, 35-50 (2002). (Pubitemid 34971552)
13. Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective b 2-adrenoceptor agonist bronchodilator. Life Sci. 52, 2145-2160 (1993).
14. Smith C, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung 48, 956-960 (1998). (Pubitemid 28427415)
15. Stellato C, Atsuta J, Bickel CA, Schleimer RP. An in vitro comparison of commonly used topical glucocorticoid preparations. J. Allergy Clin. Immunol. 104, 623-629 (1999). (Pubitemid 29451654)
16. Atsuta J, Plitt J, Bochner BS, Schleimer RP. Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids. Am. J. Respir. Cell Mol. Biol. 20, 643-650 (1999). (Pubitemid 129495652)
17. Umland SP, Nahrebne DK, Razac S et al. The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-g production by cultured primary CD4+ T cells. J. Allergy Clin. Immunol. 100, 511-519 (1997).
18. Affrime MB, Cuss F, Padhi D et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J. Clin. Pharmacol. 40, 1227-1236 (2000).
19. Skoner DP, Gentile DA, Angelini B. Effect of therapeutic doses of mometasone furoate on cortisol levels in children with mild asthma. Allergy Asthma Proc. 31, 10-19 (2010).
20. Shapiro GS, Yegen U, Xiang J et al. A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exerciseinduced bronchoconstriction by formoterol and albuterol. Clin. Ther. 24, 2077-2087 (2002). (Pubitemid 36051532)
21. Molimard M, Guenole E, Duvauchelle T et al. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients. Respiration 72(Suppl. 1), 28-34 (2005). (Pubitemid 40868763)
22. Maspero JF, Nolte H, Cherrez-Ojeda I. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. J. Asthma 47, 1106-1115 (2010).
23. Adcock IM, Maneechotesuwan K, Usmani O. Molecular interactions between glucocorticoids and long-acting beta2-agonists. J. Allergy Clin. Immunol. 110, S261-S268 (2002). (Pubitemid 35471714)
24. Chapman RW, Curran AK, House A et al. Effect of mometasone furoate (MF)/formoterol fumarate (F) combination (MF/F) on late-phase responses in allergen-challenged Brown Norway rats. Pulm. Pharmacol. Ther. 24, 67-73 (2011).
25. Nathan RA, Nolte H, Pearlman DS. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc. 31, 269-279 (2010).
26. Weinstein SF, Corren J, Murphy K et al. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy Asthma Proc. 31, 280-289 (2010).
27. Reddel HK, Taylor DR, Bateman ED et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am. J. Respir. Crit. Care Med. 180, 59-99 (2009).
28. Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim. Care Respir. J. 16, 22-27 (2007). (Pubitemid 46364352)
29. Shingo S, Zhang J, Reiss TF. Correlation of airway obstruction and patient-reported endpoints in clinical studies. Eur. Respir. J. 17, 220-224 (2001). (Pubitemid 32600581)
30. Juniper EF, Wisniewski ME, Cox FM et al. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur. Respir. J. 23, 287-291 (2004). (Pubitemid 38195516)
31. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J. Allergy Clin. Immunol. 113, 59-65 (2004). (Pubitemid 38096162)
32. Juniper EF, Bousquet J, Abetz L, Bateman ED. Identifying well-controlled' and not well-controlled' asthma using the Asthma Control Questionnaire. Respir. Med. 100, 616-621 (2006). (Pubitemid 43285748)